Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma

Journal of Immunotherapy

Volumn 35, Issue 1, 2012, Pages 89-97

  Weber, Jeffrey S ^a   Hamid, Omid ^b   Chasalow, Scott D ^c   Wu, Dianna Y ^c   Parker, Susan M ^c   Galbraith, Susan ^c   Gnjatic, Sacha ^d   Berman, David ^c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Angeles Clinic and Research Institute   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

cytotoxic T lymphocyte antigen 4; humoral immunity; ipilimumab; melanoma; T cell populations

Indexed keywords

ANTIGEN SSX2; BUDESONIDE; CD4 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; IPILIMUMAB; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 4; PLACEBO; PNEUMOCOCCUS VACCINE; PROTEIN P53; TETANUS TOXOID; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG MECHANISM; HUMAN; HUMORAL IMMUNITY; IMMUNOREACTIVITY; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MELANOMA; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HLA-DR ANTIGENS; HUMANS; IMMUNITY, HUMORAL; IMMUNOCOMPETENCE; IMMUNOLOGIC MEMORY; INDUCIBLE T-CELL CO-STIMULATOR PROTEIN; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SKIN NEOPLASMS; VACCINES;

EID: 84155163015     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31823aa41c     Document Type: Article

References (36)

1. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008;26:5275-5283.
2. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimu-latory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7:95-106.
3. Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010;37:533-546.
4. Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25:876-883.
5. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol. 2010;37:430-439.
6. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
7. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-2526.
8. Chambers CA, Kuhns MS, Egen JG, et al. CTLA-4-mediated inhibition in regulation of T-cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001;19:565-594.
9. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol. 2010;37:473-484.
10. Quezada SA, Peggs KS, Curran MA, et al. CTLA4 blockade and GM-CSF combination immunotherapy alters the intra-tumor balance of effector and regulatory T cells. J Clin Invest. 2006;116:1935-1945.
11. Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T-cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206:1717-1725.
12. Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res. 2011;71:5445-5454.
13. Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 1999;397:263-266.
14. Menard C, Ghiringhelli F, Roux S, et al. CTLA-4 blockade confers lymphocyte resistance to regulatory T cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res. 2008;14:5242-5249.
15. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol. 2005;175: 7746-7754.
16. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T-lymphocyte-associated antigen-4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372-8377.
17. Weber J, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26:5950-5956.
18. Hersh EM, O'Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs. 2010;29:489-498.
19. hi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA. 2008;105:14987-17992.
20. Sarnaik AA, Yu B, Yu D, et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res. 2010;17:896-906.
21. Carthon B, Wolchok JD, Yuan J, et al. Pre-operative CTLA-4 blockade: tolerability and immune monitoring in the setting of a pre-surgical clinical trial. Clin Cancer Res. 2010;16: 2861-2871.
22. Klein O, Ebert LM, Nicholaou T, et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res. 2009;15:2507-2513.
23. + T cells: correlation with clinical outcomes. J Clin Oncol. 2010;28(15s): abstr 2555.
24. Keler T, Halk E, Vitale L, et al. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J Immunol. 2003;171:6251-6259.
25. Boudewijns M, Jeurissen A, Wuyts M, et al. Blockade of CTLA-4 (CD152) enhances the murine antibody response to pneumococcal capsular polysaccharides. J Leukoc Biol. 2005; 78:1060-1069.
26. Yuan J, Gnjatic S, Li H, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in meta-static melanoma patients with clinical benefit. Proc Natl Acad Sci USA. 2008;105:20410-20415.
27. Hamid O, Chasalow SD, Tsuchihashi Z, et al. Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. J Clin Oncol. 2009;27(15s): abstr 9008.
28. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15: 5591-5598.
29. Adams S, O'Neill DW, Nonaka D, et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol. 2008;181:776-784.
30. S-PLUS 7.0 for UNIX User's Guide. Seattle, WA: Insightful Corporation; 2005.
31. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-7420.
32. Hodi FS, Oble DA, Drappatz J, et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol. 2008;5:557-561.
33. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA. 2008;105:3005-3010.
34. + T cells in vivo. J Immunol. 2011;186:5580-5589.
35. + T cell response. J Med Primatol. 2008;37(suppl 2):62-68.
36. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA. 2005;102:9571-9576.